AI Article Synopsis

  • Research indicates that growth factors play a significant role in lung cancer angiogenesis, which helps tumors grow and spread by affecting the immune response.
  • New treatment strategies focus on developing anti-angiogenic compounds that block the activity of these growth factors, particularly EGF and VEGF, to hinder lung cancer progression.
  • While the initial results of these therapies are promising, there is a heightened risk of toxicity, necessitating personalized follow-up care for patients undergoing treatment.

Article Abstract

Research has shown the role of growth factors in lung cancer angiogenesis. Angiogenesis promotes lung cancer progression by stimulating tumor growth, enhancing tumor invasion, contributing to metastasis, and modifying immune system responses within the tumor microenvironment. As a result, new treatment techniques based on the anti-angiogenic characteristics of compounds have been developed. These compounds selectively block the growth factors themselves, their receptors, or the downstream signaling pathways activated by these growth factors. The EGF and VEGF families are the primary targets in this approach, and several studies are being conducted to propose anti-angiogenic drugs that are increasingly suitable for the treatment of lung cancer, either as monotherapy or as combined therapy. The efficacy of the results are encouraging, but caution must be placed on the higher risk of toxicity, outlining the importance of personalized follow-up in the management of these patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526378PMC
http://dx.doi.org/10.3390/cancers15184648DOI Listing

Publication Analysis

Top Keywords

lung cancer
16
growth factors
16
growth
5
angiogenesis lung
4
cancer
4
cancer understanding
4
understanding roles
4
roles growth
4
factors
4
factors role
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!